Phase I dose escalation study of the first-in-class selective PTEFb inhibitor BAY 1251152 in patients with advanced cancer: Novel target validation and early evidence of clinical activity
| Autor: | Claudia Merz, John Lettieri, Ray Valencia, Victor Moreno, Raul Cordoba, Valentina Boni, Jennifer R. Diamond, Emerson A. Lim, Stuart Ince, Charles Cai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research business.industry Advanced cancer 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology Transcription (biology) 030220 oncology & carcinogenesis Dose escalation Cancer research Medicine Cyclin-dependent kinase 9 In patient business |
| Zdroj: | Journal of Clinical Oncology. 36:2507-2507 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.2507 |
| Popis: | 2507Background: PTEFb/CDK9 mediated transcription of short-lived anti-apoptotic survival proteins and oncogenes like MYC and MCL-1 plays a critical role in a variety of cancers. We present findings... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|